In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NuVasive makes equity investment in Progentix

Executive Summary

NuVasive (minimally invasive devices for spinal surgeries) received exclusive worldwide rights to distribute biomaterials firm Progentix Orthobiology BV's synthetic bone substitutes for ten years. Under certain circumstances, it also has the exclusive option to acquire Progentix.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes M&A Option
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register